These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32962091)

  • 1. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
    De Luca A; Esposito Abate R; Rachiglio AM; Maiello MR; Esposito C; Schettino C; Izzo F; Nasti G; Normanno N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
    Dianat-Moghadam H; Teimoori-Toolabi L
    Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of targetable FGFR gene fusions in diverse cancers.
    Wu YM; Su F; Kalyana-Sundaram S; Khazanov N; Ateeq B; Cao X; Lonigro RJ; Vats P; Wang R; Lin SF; Cheng AJ; Kunju LP; Siddiqui J; Tomlins SA; Wyngaard P; Sadis S; Roychowdhury S; Hussain MH; Feng FY; Zalupski MM; Talpaz M; Pienta KJ; Rhodes DR; Robinson DR; Chinnaiyan AM
    Cancer Discov; 2013 Jun; 3(6):636-47. PubMed ID: 23558953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR a promising druggable target in cancer: Molecular biology and new drugs.
    Porta R; Borea R; Coelho A; Khan S; Araújo A; Reclusa P; Franchina T; Van Der Steen N; Van Dam P; Ferri J; Sirera R; Naing A; Hong D; Rolfo C
    Crit Rev Oncol Hematol; 2017 May; 113():256-267. PubMed ID: 28427515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances and challenges in targeting FGFR signalling in cancer.
    Babina IS; Turner NC
    Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FGFR Signaling in Cancer.
    Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
    Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.
    Yashiro M; Matsuoka T
    World J Gastroenterol; 2016 Feb; 22(8):2415-23. PubMed ID: 26937130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.
    Chen L; Zhang Y; Yin L; Cai B; Huang P; Li X; Liang G
    J Exp Clin Cancer Res; 2021 Nov; 40(1):345. PubMed ID: 34732230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR-targeted therapeutics for the treatment of breast cancer.
    De Luca A; Frezzetti D; Gallo M; Normanno N
    Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mutant fibroblast growth factor receptors in cancer.
    Greulich H; Pollock PM
    Trends Mol Med; 2011 May; 17(5):283-92. PubMed ID: 21367659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
    Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
    Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR-TKI resistance in cancer: current status and perspectives.
    Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
    J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting FGFR in bladder cancer: ready for clinical practice?
    De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
    Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
    [No Abstract]   [Full Text] [Related]  

  • 18. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
    Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
    Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
    Chandana SR; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.